|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li L and Ma BB: Colorectal cancer in
Chinese patients: Current and emerging treatment options. Onco
Targets Ther. 7:1817–1828. 2014.PubMed/NCBI
|
|
3
|
Tokarz P and Blasiak J: The role of
microRNA in metastatic colorectal cancer and its significance in
cancer prognosis and treatment. Acta Biochim Pol. 59:467–474.
2012.PubMed/NCBI
|
|
4
|
Nana-Sinkam SP and Croce CM: Clinical
applications for microRNAs in cancer. Clin Pharmacol Ther.
93:98–104. 2013. View Article : Google Scholar
|
|
5
|
Cui Y, Bai Y, Wang XD, Liu B, Zhao Z and
Wang LS: Differential expression of miRNA in rat myocardial tissues
under psychological and physical stress. Exp Ther Med. 7:901–906.
2014.PubMed/NCBI
|
|
6
|
Shim SM, Jung SY, Nam HY, Kim HR, Lee MH,
Kim JW, Han BG and Jeon JP: Network signatures of cellular
immortalization in human lymphoblastoid cell lines. Biochem Biophys
Res Commun. 441:438–446. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang N, Lin J, Ruan J, Su N, Qing R, Liu
F, He B, Lv C, Zheng D and Luo R: MiR-219-5p inhibits
hepatocellular carcinoma cell proliferation by targeting
glypican-3. FEBS Lett. 586:884–891. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang C, Cai Z, Huang M, Mao C, Zhang Q,
Lin Y, Zhang X, Tang B, Chen Y, Wang X, et al: miR-219-5p modulates
cell growth of papillary thyroid carcinoma by targeting estrogen
receptor α. J Clin Endocrinol Metab. 100:e204–e213. 2015.
View Article : Google Scholar
|
|
9
|
Rao SA, Arimappamagan A, Pandey P, Santosh
V, Hegde AS, Chandramouli BA and Somasundaram K: miR-219-5p
inhibits receptor tyrosine kinase pathway by targeting EGFR in
glioblastoma. PLoS One. 8:e631642013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Forghanifard MM, Moghbeli M, Raeisossadati
R, Tavassoli A, Mallak AJ, Boroumand-Noughabi S and Abbaszadegan
MR: Role of SALL4 in the progression and metastasis of colorectal
cancer. J Biomed Sci. 20:62013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ardalan Khales S, Abbaszadegan MR,
Abdollahi A, Raeisossadati R, Tousi MF and Forghanifard MM: SALL4
as a new biomarker for early colorectal cancers. J Cancer Res Clin
Oncol. 141:229–235. 2015. View Article : Google Scholar
|
|
12
|
Böhm J, Sustmann C, Wilhelm C and Kohlhase
J: SALL4 is directly activated by TCF/LEF in the canonical Wnt
signaling pathway. Biochem Biophys Res Commun. 348:898–907. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He J, Zhang W, Zhou Q, Zhao T, Song Y,
Chai L and Li Y: Low-expression of microRNA-107 inhibits cell
apoptosis in glioma by upregulation of SALL4. Int J Biochem Cell
Biol. 45:1962–1973. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Prenen H, Vecchione L and Van Cutsem E:
Role of targeted agents in metastatic colorectal cancer. Target
Oncol. 8:83–96. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oestreicher P: Sequencing therapies: The
role of targeted agents in metastatic colorectal cancer. ONS
Connect. 22(Suppl 8): 37–38. 2007.PubMed/NCBI
|
|
16
|
Iqbal N and Iqbal N: Imatinib: A
breakthrough of targeted therapy in cancer. Chemother Res Pract.
2014:3570272014.PubMed/NCBI
|
|
17
|
Balduzzi S, Mantarro S, Guarneri V,
Tagliabue L, Pistotti V, Moja L and D'Amico R:
Trastuzumab-containing regimens for metastatic breast cancer.
Cochrane Database Syst Rev. 6:CD0062422014.PubMed/NCBI
|
|
18
|
Gustavsson B, Carlsson G, Machover D,
Petrelli N, Roth A, Schmoll HJ, Tveit KM and Gibson F: A review of
the evolution of systemic chemotherapy in the management of
colorectal cancer. Clin Colorectal Cancer. 14:1–10. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alberts SR, Sargent DJ, Nair S, Mahoney
MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S,
et al: Effect of oxaliplatin, fluorouracil, and leucovorin with or
without cetuximab on survival among patients with resected stage
III colon cancer: A randomized trial. JAMA. 307:1383–1393. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tveit KM, Guren T, Glimelius B, Pfeiffer
P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund
E, et al: Phase III trial of cetuximab with continuous or
intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic
FLOX) versus FLOX alone in first-line treatment of metastatic
colorectal cancer: The NORDIC-VII study. J Clin Oncol.
30:1755–1762. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seymour MT: Adjuvant bevacizumab in colon
cancer: Where did we go wrong? Lancet Oncol. 13:1176–1177. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sculier JP, Berghmans T and Meert AP:
Advances in target therapy in lung cancer. Eur Respir Rev.
24:23–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y, Wang X, Wang Z, Tang H, Fan H and
Guo Q: miR-182 promotes cell growth and invasion by targeting
forkhead box F2 transcription factor in colorectal cancer. Oncol
Rep. 33:2592–2598. 2015.PubMed/NCBI
|
|
24
|
Tang L, Chen F, Pang EJ, Zhang ZQ, Jin BW
and Dong WF: MicroRNA-182 inhibits proliferation through targeting
oncogenic ANUBL1 in gastric cancer. Oncol Rep. 33:1707–1716.
2015.PubMed/NCBI
|
|
25
|
Jiang Z, Cushing L, Ai X and Lü J: miR-326
is downstream of Sonic hedgehog signaling and regulates the
expression of Gli2 and smoothened. Am J Respir Cell Mol Biol.
51:273–283. 2014.PubMed/NCBI
|
|
26
|
Leung WK, He M, Chan AW, Law PT and Wong
N: Wnt/β-Catenin activates MiR-183/96/182 expression in
hepatocellular carcinoma that promotes cell invasion. Cancer Lett.
362:97–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yong KJ, Gao C, Lim JS, Yan B, Yang H,
Dimitrov T, Kawasaki A, Ong CW, Wong KF, Lee S, et al: Oncofetal
gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med.
368:2266–2276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao C, Kong NR and Chai L: The role of
stem cell factor SALL4 in leukemogenesis. Crit Rev Oncog.
16:117–127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang J, Chai L, Liu F, Fink LM, Lin P,
Silberstein LE, Amin HM, Ward DC and Ma Y: Bmi-1 is a target gene
for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci
USA. 104:10494–10499. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gao C, Dimitrov T, Yong KJ, Tatetsu H,
Jeong HW, Luo HR, Bradner JE, Tenen DG and Chai L: Targeting
transcription factor SALL4 in acute myeloid leukemia by
interrupting its interaction with an epigenetic complex. Blood.
121:1413–1421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kang W, Tong JH, Lung RW, Dong Y, Zhao J,
Liang Q, Zhang L, Pan Y, Yang W, Pang JC, et al: Targeting of YAP1
by microRNA-15a and microRNA-16-1 exerts tumor suppressor function
in gastric adenocarcinoma. Mol Cancer. 14:522015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang ZW, Men T, Feng RC, Li YC, Zhou D
and Teng CB: miR-375 inhibits proliferation of mouse pancreatic
progenitor cells by targeting YAP1. Cell Physiol Biochem.
32:1808–1817. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu SJ, Hu JY, Kuang XY, Luo JM, Hou YF, Di
GH, Wu J, Shen ZZ, Song HY and Shao ZM: MicroRNA-200a promotes
anoikis resistance and metastasis by targeting YAP1 in human breast
cancer. Clin Cancer Res. 19:1389–1399. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gebert LF, Rebhan MA, Crivelli SE, Denzler
R, Stoffel M and Hall J: Miravirsen (SPC3649) can inhibit the
biogenesis of miR-122. Nucleic Acids Res. 42:609–621. 2014.
View Article : Google Scholar
|
